ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1361

How Often Do Rheumatologists Use Valid Prognostic Factors of Rheumatoid Arthritis? the Progresar Project

Teresa Oton-Sanchez1, Loreto Carmona2, Sara Luján3, Ana Royo3, Jose Luis Baquero4 and Santiago Muñoz-Fernandez5, 1InMusc. Instituto de Salud Músculo-Esquelética, Madrid, Spain, 2Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 3Medical Department Bristol-Myers Squibb, Madrid, Spain, 4Scientific Department Scientia Salus, Madrid, Spain, 5Rheumatology, Hospital Universitario Infanta Sofia. Universidad Europea, Madrid, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Prognostic factors and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Prognostic factors facilitate decisions on treatment and follow-up of patients with rheumatoid arthritis (RA). Rheumatologists might use factors with poor link to evidence in clinical practice. The ProgresAR project aims to 1) benchmark the use of the most commonly known prognostic factors in RA in daily clinical practice, and 2) to contrast their use with the strength of association of these factors with poor outcome.

Methods: We performed an overview of systematic reviews of factors associated with disability, mortality, remission, and radiological progression in RA. Then, a panel of rheumatologists, removed and added factors to the selection. Following, a review in matrix was carried out for each factor and outcome. In parallel, a group of 42 rheumatologists randomly selected was surveyed. The use of each factor was recorded on a Likert scale from 1 (none) to 9 (always) generating 3 categories: 1-3 under use; 4-6 intermediate and 7-9 high use.

Prognostic factors

Use

M (IQR)

Radiological progression

Disability

Mortality

Remission

Sociodemographic data

Advanced age

5 (4)

C

C

Female gender

6 (4)

C

NN

C

Low educational level

5 (3)

N

C

Low sociocultural level

6 (4)

N

N

N

Medical history and clinical presentation

Interstitial lung disease

8 (1)

N

Very young onset

7 (3)

Nn

C

NN

Disease duration

8 (3)

C

N

Comorbidity and toxic habits

Tobacco use

8 (2)

C

N

Obesity

6 (2)

C

P

N

Depression

6 (3)

N

N

Baseline low bone mineral density

6 (2)

NN

Cardiovascular disease or risk factors

8 (1)

N

N

Other comorbidities (infections, liver disease, chronic kidney disease …)

8 (2)

N

N

Questionnaires or indices

Activity (DAS28 score, SDAI…)

9 (1)

N

N

Function (HAQ)

7 (2)

C

NN

N

Biomarkers

Rheumatoid factor

9 (2)

NNN

N

N

Anti-citrullinated peptide antibodies (ACPA)

9 (1)

NNNN

N

NN

Acute phase reactants

9 (1)

N

N

Calprotectin

2 (2)

N

Interleukin-2

1 (1)

NN

Receptor Activator for Nuclear Factor K B Ligand

1 (2)

N

Vitamin D deficit

6 (4)

NN

NN

Genetic markers

Shared epitope

2 (4)

NNN

N

NN

NN

Image data

Ultrasound synovitis with Doppler signal

7 (2)

NN

Osteitis by magnetic resonance

4 (4)

NN

Erosions by magnetic resonance

4 (4)

NNN

Erosions by radiography

9 (1)

NNN

N

N

Erosions by ultrasound

7 (3)

N

M: median; IQR: interquartile range; C: controversial; N/n: negative effect; P: positive effect. The number of letters indicates the strength of the association, from weak (N) to strong (NNNN). Lowercase (n) indicates an intermediate assessment.


Results: The reviews identified 36 prognostic factors that were further reduced to 28. The survey was completed by 42 rheumatologists. Table 1 shows, for each factor, the reported frequency of use and the strength of association with the various outcomes.

Conclusion: Rheumatoid factor, ACPA, and erosions by radiography are well recognized and strong predictors that are used frequently. Osteitis and erosions by magnetic resonance and shared epitope have good evidence but minor use. Disease duration and smoking are frequently used as prognostic factors despite weak association with outcome, similarly to activity and acute phase reactants at baseline. Subsequently, we will test whether displaying the evidence makes rheumatologists change opinions.


Disclosure: T. Oton-Sanchez, Bristol-Myers Squibb., 2; L. Carmona, Bristol-Myers Squibb., 2; S. Luján, Bristol-Myers Squibb., 3; A. Royo, Bristol-Myers Squibb., 3; J. L. Baquero, Bristol-Myers Squibb., 2; S. Muñoz-Fernandez, Bristol-Myers Squibb., 2.

To cite this abstract in AMA style:

Oton-Sanchez T, Carmona L, Luján S, Royo A, Baquero JL, Muñoz-Fernandez S. How Often Do Rheumatologists Use Valid Prognostic Factors of Rheumatoid Arthritis? the Progresar Project [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/how-often-do-rheumatologists-use-valid-prognostic-factors-of-rheumatoid-arthritis-the-progresar-project/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-often-do-rheumatologists-use-valid-prognostic-factors-of-rheumatoid-arthritis-the-progresar-project/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences